ADDF’s Seed Funding Leads to FDA Approval of Amyvid™, First Diagnostic Test for Alzheimer’s Disease

The Alzheimer’s Drug Discovery Foundation (ADDF) is very pleased that the US Food and Drug Administration (FDA) has approved Amyvid™ (florbetapir F18 injection), the first diagnostic test for Alzheimer’s disease. This approval marks an important milestone for early detection, diagnosis, treatment and patient care of Alzheimer’s disease and other cognitive disorders.

The ADDF is proud of its important role in the early development of Amyvid™, as providers of the critical seed funding for research that led to the diagnostic’s development and approval.

This approval is important proof-of-concept evidence of the success of the ADDF’s venture philanthropy model, showcasing how early financial support for high-risk projects can create innovation and accelerate the development of novel treatments and diagnostics.

For additional information, please view the FDA press release here.